High Finance with Peter Su ft. Beau Whitney: Founder & CEO: Whitney Economics
About the Author: HCN News Team
Related Posts
Latest News
BREAKING: MAPS Wins FDA Approval for Clinical Trials of Medical Cannabis
SAN JOSE-- The U.S. Food and Drug Administration (FDA) Division of Psychiatry Products has cleared the Multidisciplinary Association for Psychedelic Studies (MAPS)’ Phase 2 study of smoked cannabis in Veterans for the treatment of PTSD ...
Curaleaf Secures Massachusetts’ First Cannabis Research License
LOS ANGELES- In a significant development for the cannabis industry, Curaleaf Holdings, Inc., a leading multistate operator, has secured Massachusetts' inaugural cannabis research facility license. The Massachusetts Cannabis Control Commission (CCC) unanimously approved the license ...
Cybin Reports 79% Remission in MDD with CYB003, Prepares for Phase 3 Trials
LOS ANGELES- Cybin Inc., has announced promising results from its Phase 2 study of CYB003, a proprietary deuterated psilocybin analog developed for the treatment of major depressive disorder (MDD). The study demonstrated that 79% of ...
